Lee Herman, MD
Internal Medicine · Suwanee, GANPI 1184779027
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,817 of the $13,675 with a category attached, or 64.5%. 47 manufacturers reported payments, led by Novo Nordisk at 27.7% of the total. Reporting peaked in 2020 at $4,520 and has fallen 85.0% since, to $679 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 550 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Bayer$3K
- Amgen$1K
- Eli Lilly$598
- AstraZeneca$572
- AbbVie$417
- plus $4K from 41 others
Across 281 payments — averaging $3572.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$519K
- Amgen$215K
- Novo Nordisk AS$188K
- AbbVie$49K
- Sanofi US Services Inc.$13K
- Alnylam Pharmaceuticals Inc.$9K
- plus $12K from 3 others
What the payments were for
- Consulting fees$3,53926%
- Travel & lodging$1,2999%
- Food & beverage$8,81764%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,675 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $79,257 |
| Repatha SureclickEvolocumab | 47 | $73,179 |
| MounjaroTirzepatide | 56 | $72,117 |
| JardianceEmpagliflozin | 58 | $71,568 |
| JanuviaSitagliptin Phosphate | 53 | $61,378 |
| FarxigaDapagliflozin Propanediol | 35 | $50,807 |
| ProliaDenosumab | 25 | $39,652 |
| EliquisApixaban | 34 | $35,436 |
| TrulicityDulaglutide | 22 | $32,306 |
| KerendiaFinerenone | 38 | $31,090 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $28,610 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 91 | $27,724 |
| Praluent PenAlirocumab | 14 | $16,590 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $11,403 |
| LivaloPitavastatin Calcium | 20 | $10,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $347 | $104,42378 claims |
| Novo NordiskOzempic | $3,792 | $79,25760 claims |
| Boehringer IngelheimJardiance | $193 | $71,56858 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $412 | $66,444161 claims |
| MerckJanuvia | $41 | $61,37853 claims |
| AstraZenecaFarxiga | $572 | $50,80735 claims |
| AmgenProlia | $1,200 | $39,65225 claims |
| PfizerEliquis | $289 | $35,43634 claims |
| BayerKerendia | $3,090 | $31,09038 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $320 | $10,17220 claims |
| AbbVieSynthroid | $417 | $2,35245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Suwanee
- Michael ConlinSuwanee$40K
- Jinahn KimSuwanee$23K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.